Background: The role of radical prostatectomy in treating non-metastatic prostate cancer patients with high prostate-specific antigen levels remains unclear. We evaluated the feasibility and oncological outcomes of radical prostatectomy in non-metastatic prostate cancer patients with prostatespecific antigen levels of 50 ng/ml or higher. Methods: This retrospective study included 31 patients who were diagnosed as very high-risk prostate cancer (clinical stage of any T, N0-1 M0 and PSA levels ≥50 ng/ml) and underwent radical prostatectomy either as a monotherapy or as a component of multimodal therapy (RP group). Surgery-related complications were investigated. Time to castration-resistant prostate cancer, cancer-specific survival, and overall survival were estimated using the Kaplan-Meier method. A total of 47 patients with very high-risk prostate cancer who were treated with androgen deprivation therapy without local therapy served as a control group (ADT group). Survivals were compared between RP group and ADT group in exploratory analyses. Results: The median pretreatment prostate-specific antigen was 87 ng/ml and 100 ng/ml in the RP and ADT groups, respectively (P = 0.67). Surgical complications of Clavien-Dindo Grade 3 were documented in nine patients (29%). Ten-year castration-resistant prostate cancer-free, cancer-specific and overall survivals were 78%, 81% and 77% in RP group, respectively, and they were significantly better than those of ADT group (54%, P = 0.006; 54%, P = 0.006 and 38%, P < 0.001). Exploratory multivariate analysis identified radical prostatectomy as the only significant factor associated with a better cancer-specific survival (hazard ratio: 0.25, P = 0.006). Conclusions: Radical prostatectomy is feasible for non-metastatic prostate cancer patients with prostate-specific antigen levels of 50 ng/ml or higher. Radical prostatectomy is a viable option for select patients with non-metastatic, very high-risk prostate cancer.
Introduction
Radical prostatectomy (RP) has been established as a standard treatment for non-metastatic, localized prostate cancer (PCa). Most lowand intermediate-risk PCas have been considered as viable candidates for RP, although RP may be beneficial even for those with highrisk features (>cT2, and/or GS > 7, and/or prostate-specific antigen (PSA) >20 ng/ml) (1, 2) . The updated guidelines advocate RP in a multimodality setting for patients with high-risk, localized PCa and a life expectancy of >10 years (3, 4) . However, the indication of RP for PCa with very high-risk features (i.e., PSA >50 ng/ml) remains unknown.
High serum PSA levels at diagnosis is associated with advanced stage and a poor prognosis (3) . Patients with extremely high PSA levels are likely to harbor disseminating metastases, even without diagnostic imaging evidence of distant lesions. RP is not typically considered for local treatment of the primary tumor in this scenario, whereas androgen deprivation therapy (ADT) represents the main therapy (5) .
Recently, local treatment has been suggested to play an active role in the management of non-metastatic, very high-risk PCa (2, 6) . A Canadian study showed radiation therapy (RT) prolonged cancerspecific survival (CSS) in patients with ultra-high PSA and nonmetastatic disease, compared with ADT alone (10-year CSS for the patients with PSA > 100 ng/ml, 54% vs. 32%, respectively) (7) . A few studies have reported 10-year CSS rates of 80-86% CSS in PCa patients with ultra-high PSA levels undergoing RP (1, 8) , although these studies lacked comparative treatment groups.
In this retrospective study, we investigated feasibility and oncological outcomes of RP in multimodal therapy settings in a selected cohort of patients with very high-risk, non-metastatic PCa (i.e., PSA > 50 ng/ml, any T, N0-1 M0). Using a cohort of patients treated with ADT alone as a study control, we explored the oncological role of RP in these patients.
Materials and methods
This study was approved by the institutional review board of Ome Municipal General Hospital. Written informed consent was obtained from all individual participants included in the study. We retrospectively reviewed the institutional database of 472 PCa patients treated at our hospital between January 1999 and December 2016. Those patients with clinical stages of any T, N0-1 M0 and PSA levels of 50 ng/ml or greater were eligible for the analysis (n = 85). All patients underwent bone scintigraphy and abdomen-pelvis computed tomography for metastasis assessment. After excluding patients receiving RT as the primary treatment (n = 7), a total of 78 patients formed the basis of the current study cohort.
Among the 78, a total of 31 patients underwent open retropubic RP and staging pelvic lymphadenectomy of obturator nodes without neurovascular bundle preservation (RP group). Indications of RP were determined based on patients' treatment preference, a life expectancy of over 10 years, and resectability as assessed by imaging studies and digital rectal examination. In 23 cases, neoadjuvant, and/or adjuvant hormonal therapy (HT), or adjuvant RT was administered.
Treatment protocol in RP group
Neoadjuvant HT was administered at the physicians' discretion based on biopsy Gleason score and serum PSA level. Post-RP adjuvant HT was further offered in the cases with positive nodes or biopsy Gleason score 10. Patients without neoadjuvant HT received adjuvant HT if their pathology demonstrated positive nodes or pT3b/pT4 or pT3a and positive surgical margin (Fig. 1) .
Control group
Out of the 78 patients, the remaining 47 were treated with ADT only, without any local therapy. They served as the study control (ADT alone group). 
Follow-up
Patients were followed-up regularly at our outpatient clinic. Followup examinations generally consisted of medical history, physical examination and measurement of the serum PSA. Imaging studies were indicated only when clinical symptoms were noted.
Definition of progression
For the patients in the RP group, biochemical recurrence (BCR) was defined as two consecutive instances of elevated PSA values >0.2 ng/ ml (9) . Upon BCR, patients underwent salvage HT, RT to the prostate bed, or both. Castration-resistant prostate cancer (CRPC) was defined as BCR or the appearance of new lesions in imaging studies under ADT (9, 10) . CRPC in the ADT alone group was defined by three consecutive instances of elevated PSA levels, resulting in two 50% increases over the nadir with PSA values >2 ng/ml (9) .
CRPC-free survival was measured as the time from the date of diagnosis to the development of CRPC. CSS and overall survival (OS) was defined as the time from diagnosis to death, attributed to PCa, and to death from any cause, respectively.
Statistical analysis
All categorical variables were analyzed by the chi-square test and continuous variables were compared using the Mann-Whitney U-test. Kaplan-Meier analysis was used to estimate CRPC-free survival, CSS and OS, including the calculation of 95% confidence intervals (95% CI) of survival. Cox proportional hazards regression models were used for univariate and multivariate analyses. Statistical computations were carried out using JMP 11.0.0 (SAS Institute, Cary, NC, USA). Significance was set at a P value of P < 0.05.
Results

Patient characteristics
Demographic features and tumor characteristics are shown in Table 1 . Of the 78 analyzed patients, 38 (49%) had an initial PSA level of 100 ng/ml or greater. The median PSA was 87 ng/ml (interquartile range, IQR: 59-162 ng/ml) in the RP group and 100 ng/ml (IQR: 66-152 ng/ml) in the ADT alone group (P = 0.67). Patients in the RP group were significantly younger than those in the ADT alone group (mean 68 vs. 78 years, P < 0.001). Other patient characteristics in terms of Charlson comorbidity index, biopsy Gleason score and clinical stage were not significantly different between treatment arms.
Histopathology and neoadjuvant/adjuvant treatments
Histological characteristics, neoadjuvant/adjuvant treatments and surgical complications in the RP group are shown in Table 2 ; nine patients (29%) received neoadjuvant HT (median 12 months, IQR: 6-20 months), four patients (13%) underwent castration at the same time as RP, and a LH-RH agonist and/or an anti-androgen agent were administered to 12 patients (39%) as adjuvant HT. Two patients (6%) received adjuvant RT (Fig. 1) .
Surgical pathology identified six patients (19%) with pT2, 13 (42%) with pT3a, 11 (36%) with pT3b, and 1 (3%) with pT4; 7 (23%) were pN1. Twenty-one cases (68%) had positive surgical margins.
Complications of RP
In the RP group, nine patients (29%) suffered from surgical complications of Clavien-Dindo Grade 3, including rectal injury (3/31; 10%), anastomotic stricture (6/31; 19%) and wound dehiscence (1/31; 3%). No Grade 4 or 5 complications were observed. Mean blood loss was 1994 ml (IQR: 940-2475 ml), and 12 patients (39%) received allogeneic erythrocyte transfusions.
Among three patients with rectal injury, one patient with PSA of 946 ng/ml had received neoadjuvant HT, and the other two had not. All rectal injuries were diagnosed and repaired intraoperatively without colostomy. Lesions were primarily closed with two layers sutures. A fat flap was not placed. Broad-spectrum antibiotics and intravenous hyperalimentation were prescribed. Patients resumed oral intake within 7-14 days. Urethral anastomotic stricture was assessed using urethrocystography and cystoscopy. All patients were initially treated endoscopically with cold knife incision. One patient developed recurrent stenosis with a bladder stone 105 months after initial internal urethrotomy, and incision using holmium:YAG laser resulted in urinary incontinence for one year. Another patient underwent open surgery due to obliterative stricture.
Incontinence defined as use of two or more pads a day was recorded in two patients (6%) at the final follow-up.
Oncological outcomes of RP
In the RP group, the median follow-up time was 100 months (IQR: 58-137 months). During follow-up, BCR occurred in 17 patients (55%), at a median of 20 months. All of these patients received salvage RT (7/17; 40%) and/or HT (13/17; 76%). Six patients (19%) progressed to CRPC, with four (13%) eventual deaths. The 10-year CRPCfree survival, CSS and OS were 78% (95% CI, 57-93%), 81% (95% CI, 72-90%) and 77% (95% CI, 54-90%), respectively (Fig. 2) .
Notably, among the eight patients without neoadjuvant nor adjuvant ADT, seven patients (88%) achieved nadir PSA levels of 0.2 ng/ml or less. However, all seven patients eventually developed BCR. Median BCR-free time in these eight patients was 9 months (IQR: 9-20 months) ( Supplementary Fig. 1 ). Figure 2 . Castration-resistant prostate cancer-free survival (A), cancer-specific survival (B) and overall survival (C) for the 78 patients with very high-risk prostate cancer.
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Exploratory comparative analysis of oncological outcomes
In the ADT alone group, the median follow-up time was 56 months (IQR: 33-88 months). Of these 47 patients, 16 (34%) progressed to CRPC, with all becoming deceased due to progression of PCa. Figure 2 shows estimates of the CRPC-free survival, CSS, and OS using Kaplan-Meier analysis, with stratification by treatment modality. The 10-year CSS was significantly higher in the RP group (81%; 95% CI, 72-90%), as compared with patients in the ADT alone group (54%; 95% CI, 45-64%) (P = 0.006). The 10-year CRPC-free survival and OS were also significantly higher in the RP group than the ADT alone group (78% vs. 54%, P = 0.006; 77% vs 38%, P < 0.001, respectively).
The associations of clinicopathological factors with CSS are shown in Table 3 . Univariate analyses identified age at diagnosis and RP treatment as factors significantly associated with CSS. Exploratory multivariate analysis identified RP treatment as the sole significant factor associated with an improved CSS (hazard ratio: 0.25, P = 0.006).
Discussion
The present study showed that RP was feasible in males with very highrisk PCa, although some significant complications were noted. Moreover, it indicated that RP, combined with neoadjuvant/adjuvant therapies, offered excellent CSS in these patients. Treatment with RP was significantly better than ADT alone, in terms of survivals.
In general, high PSA values are suggestive of the presence of a large amount of tumor cells. In cases with extremely high PSA values, HT with or without RT is preferred to RP, due to a concern for possible micrometastases and a high likelihood of positive surgical margins (4). However, some studies reported favorable results with RP in patients with extremely high PSA values. Inman et al. reported that patients with PSA values of 50 ng/ml or greater showed an excellent 10-year CSS rate of 87% after treatment with RP (11). Gontero et al. reported 10-year CSS rates of 85% and 80% for patients with PSA values of 50-100 ng/ml and 100 ng/ml or greater after RP, respectively (1). In our study, patients undergoing RP had a 10-year CSS rate of 81%, which was significantly better than that of ADT alone (54%). Therefore, we have confirmed the favorable prognosis of RP for very high-risk PCa as reported previously, and found its superiority over PCa treatment of ADT alone.
The reason for a survival benefit with local treatment in advanced cancer is not fully understood. In reality, local treatment of the primary tumor could improve survival outcomes, even in metastatic prostate cancer (10, (12) (13) (14) and other metastatic cancers including breast, kidney, colon, and ovarian cancers (15) (16) (17) (18) . Local treatments may reduce tumor burden, eliminate cancer stem cells in the primary tumor, or remove the primary source of the dissemination of metastatic cells (19, 20) .
Extremely high serum PSA values in PCa often indicate local invasion into the adjacent organs. In this study, RP resulted in relatively high complication rates, including three cases (10%) of rectal injury and six cases (19%) of other types of Clavien-Dindo Grade 3 complications. Rectal wall penetration could be repaired intraoperatively and managed primarily without colostomy in all cases. We assessed the resectability of the prostate by digital rectal examination before RP, but in these cases the prostate adhered firmly to the rectum and we therefore could not find the appropriate layer to dissect during surgery. Magnetic resonance imaging, which was not available during the early period of this study, would provide more information of local extension of the tumor before surgery.
Our study has several limitations. First, this is a retrospective study with a small sample size. Particularly, the decision of surgery was based largely on the physician's subjective evaluation, leading to significant selection bias. Indication of neoadjuvant/adjuvant therapies was not standardized. Thus, our results of survival comparisons between RP and ADT groups should be considered exploratory until a future prospective study with a larger cohort will provide further evidence. Second, RP was limited to open surgery. Robot-assisted laparoscopic RP could improve safety and feasibility, even for locally advanced PCa by reducing blood loss, complication rates and positive surgical margin rates (21) (22) (23) . Third, sensitivity and specificity of standard CT and bone scan are not satisfactory in the evaluation of distant metastasis. Under-staging was possible in our study cohort because of overlooked disseminated lesions. New modalities including 11C-Choline-PET/CT and 68Ga-PSMA-PET/CT may refine the detection of micrometastasis (24) . Fourth, it is unclear which patients with very high-risk features get benefit from RP. Two patients in RP group died within 5 years after RP, and it is unclear whether RP contributed to their survivals or not. Fifth, we could not compare the result of RP with that of RT, in spite of the fact that RT may be preferred than RP in this high-risk setting (7). Tai et al. reported 10-year CSS rates of 55% and 54% after RT for patients with locally advanced PCa with PSA levels of 50-99.9 ng/ml, and 100 ng/ml or greater, respectively (7).
In conclusion, RP was feasible for patients with PSA values of 50 ng/ml or greater, which resulted in 10-year CSS rate of 81% in selected cases when combined adjuvant therapies. RP would be considered as a vital option for selected patients with non-metastatic, very high-risk PCa.
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